Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 11.50 25,000 01:00:00
Bid Price Offer Price High Price Low Price Open Price
11.00 12.00 11.50 11.50 11.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 13.55 -6.91 -0.40 15
Last Trade Time Trade Type Trade Size Trade Price Currency
09:36:51 O 25,000 11.0000 GBX

Omega Diagnostics (ODX) Latest News (1)

More Omega Diagnostics News
Omega Diagnostics Takeover Rumours

Omega Diagnostics (ODX) Share Charts

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Omega Diagnostics (ODX) Discussions and Chat

Omega Diagnostics Forums and Chat

Date Time Title Posts
14/10/201909:50Omega Diagnostics - nicely poised for significant growth1,948
23/9/201909:31Omega Diagnostics1,775

Add a New Thread

Omega Diagnostics (ODX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-10-15 08:36:5111.0025,0002,750.01O
View all Omega Diagnostics trades in real-time

Omega Diagnostics (ODX) Top Chat Posts

DateSubject
15/10/2019
09:20
Omega Diagnostics Daily Update: Omega Diagnostics Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker ODX. The last closing price for Omega Diagnostics was 11.50p.
Omega Diagnostics Group Plc has a 4 week average price of 10p and a 12 week average price of 8.50p.
The 1 year high share price is 18.10p while the 1 year low share price is currently 8.50p.
There are currently 133,307,010 shares in issue and the average daily traded volume is 21,948 shares. The market capitalisation of Omega Diagnostics Group Plc is £15,330,306.15.
29/9/2019
16:12
barrywhit: bomber, two good posts. If Nigerian approval and WHO Approval are granted in the next 12 months there will be no need for any other funding, also there is the chance of some options being taken up, but wouldn’t bank on that unless the share price reaches double what it is at present..but the company are now in a strong position...The placing has certainly helped...
29/9/2019
15:17
bomber13: Having re-read the annual report and recent announcements this morning , the following three points struck me - 1) Omega has constructed detailed forecasts of funding requirements for the next 12 months having made assumptions on the timing of Visitect approvals by Nigeria and the WHO . Nigeria's MOH is expected to approve Visitect by November , 2019 , and WHO approval is expected sometime in the next financial year to March , 2021 . This latter approval was previously said to be March/April 2020 by Colin King at the Investor Briefing in August , so this new assumption would seem to be hugely and conservatively risked . 2) Omega had an overdraft of £1.3m at the beginning of September , and no long term debt . The recent placing is raising £1.6m net providing it is approved at the General Meeting on 10th October . Given that current trading is in line with management expectations , that Omega has tax losses of £6.5m ( nearly 75% of current turnover ) to utilise against future profits , and that the fundraising will wipe out debt in one fell swoop , might the management be fairly accused of being overly risk averse ? 3) Under normal market circumstances , any placing of over 10% of a company's issued capital at a 15% discount to the share price would witness some immediate flipping by placees . Astonishing therefore that we have seen nothing of that ilk in Omega's shares , the shares are well bid and now challenging the falling 200 DMA . Either the placees are absolutely rock solid and are playing the long game or the market has guessed , quite rightly in my view , that this is the last issue of cheap shares in Omega for some time .............or both . We will shortly have more meat on the bone with a trading update for the interim 6 months due in mid-October . Four shareholding groups , namely Sneller , Harwood Capital , Legal & General , and past /present directors , now control over half of Omega , and I , for one , plan to follow the money .
28/9/2019
11:52
bomber13: Following the recent placing , management ( admittedly including the ex-Chairman ) , now hold 5.2% of Omega , up from 4.8% last year , but perhaps of greater interest are the 5.3m options still outstanding , all now vested and representing 3.5% of the new issued capital . The exercise prices vary from 13p to 30.5p , but , importantly , the condition attached to all of the CEO's options , and the bulk of the CFO's and Sales Director's options is that they can only be exercised if the share price has hit 50p before expiry . That's what I call a decent carrot , and aligns their interests with our own .
23/9/2019
14:31
dibs61: David - Despite your personal slur on me which I will ignore since it says more about you than it says about me, my point stands. You and the board have failed to deliver shareholder value. That is undisputed by the share price. What you have delivered is equity dilution in the past two years by the bucket load. You say I should be thankful that I haven't lost everything because the company raised yet more funds. Tell me David who got the company into the situation whereby it had to raise all those extra funds? Was it me or my fellow shareholders? NO it was you and the board of directors. So take some responsibility man and show some humility and less arrogance!
23/9/2019
08:45
rivaldo: Indeed. Soundings for the placing would have been initiated before the recent rise, so the discount to the share price at the time would have been minimal. And this secures the company's Balance Sheet going forward nicely, thus reassuring potential and existing customers and suppliers. I see that in addition to the directors' participation, Richard Sneller is taking another 7.5m shares (£750,000). All three divisions are now looking promising for the current year and beyond. I'm particularly glad to see the core revenue-generating Food Intolerance division looking so promising - this is the bedrock upon which CD4 can be launched. I'm hopeful for at minimum steady progress this year, whilst it's possible we'll get much better than that with potential CD4 news flow, plus Food Intolerance expansion in China and the USA and the expansion of the allergy test panel via IDS.
23/9/2019
07:15
longshanks: Don't be silly, likitorma. A placing is not a bad thing: the stock market exists to facilitate such fund raising and it shows a very real appreciation of the company's value by investors.Pity the company that cannot get a placing away. In this case they have done so at a small discount to the current share price so I am not that bothered.
17/9/2019
09:33
upomega: Personally I feel the wider market has not cottoned on to how important the ERPD validation is. My understanding is that this bridges the gap before who approval. The company was proactive in applying who approval prior to this announcement thus reducing the timescale for who approval . In my opinion this is an amazing achievement for a company of this size. I liken it to a pharmaceutical going through phase1,phase2 and phase3 trial,s . We just now need an order coming through on the back of this together with the final results published and hopefully we should see some good progress with the share price.
27/8/2019
18:05
bomber13: Agreed Barryhit , the CEO sounded keen in informal discussions before the meeting , but the shares were 8.5p back then , and , who knows , if they get ERPD approval for Visitect 200 and a further Chinese order for Food Detective before the results , the share price might yet be considerably higher by the time he and other insiders are allowed to deal . However , if the directors believe in a successful 3 - 5 year long game , which , after all , they are encouraging us to believe in , the shares will still be cheap at 15p , a level that is coincidentally Richard Sneller's average in-price for 22% of the company .
31/7/2019
14:36
buywell3: Another recap Sometimes it pays to listen buywell3 - 21 Jun 2017 - 08:19:15 - 62 of 1659 Omega Diagnostics - nicely poised for significant growth - ODX To what extent is or has CD4 been the catalyst for the last rise ? That needs answering, I have already posted my thoughts . I think the BOD was extremely premature in informing the market of this product when it was clearly beset by some issues which have dragged on. The share price to date has been held up by a single buyer it seems Which in itself has some risk I also raised the issue re licence .... which I see as another unresolved risk Then there is India which I have not even bothered to look into till the chart resolves itself The share might now rise due to the 'buywell effect'' it happens quite often
23/12/2018
15:35
gwr7: Hyperboreus6 Apr '18 - 10:53 - 589 of 996 "Another 8 months away yet but Messrs Evans, Shepherd and Harbinson each have options granted on 10 December 2008 with an exercise price of 19p which expire on 10 December 2018. No idea what is likely to propel the share price north of 19p in the short term, just shows how their expectations of how Omega would perform over the last 10 years have just not materialised. In a perverse way I almost hope that the share price doesn't rise too much this year as they do not deserve to profit from them in my opinion, that is my 'gripe of the day' out of the way now!" Well you got your wish Mr. H and the positive trading update on 10th October didn't push the share price above 19p before their options expired. Colin King, CEO of Omega commented: "We are making great progress implementing our revised strategic direction and the narrower focus is already starting to deliver in our three key areas. Overall, we believe the actions we are taking will ultimately deliver shareholder value both in the short and long term." How long is the short term? Have a good Christmas.
Omega Diagnostics share price data is direct from the London Stock Exchange
Your Recent History
LSE
ODX
Omega Diag..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191016 04:41:38